AcquisitionsMay 28, 2026, 08:41 AM
SciSparc's NeuroThera Gets Approval for CliniQuantum Acquisition
AI Summary
SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs Inc., received conditional regulatory approval from the TSX Venture Exchange for the acquisition of approximately 54% interest in CliniQuantum Ltd. The transaction involves NeuroThera issuing 56.6 million common shares, valued at about $9.46 million, to CliniQuantum's selling shareholders. CliniQuantum specializes in applying quantum simulation to clinical trial data analysis, holding an exclusive license for relevant patents. The companies have extended the closing date to June 1, 2026, to fulfill remaining conditions.
Key Highlights
- NeuroThera Labs received conditional TSX Venture Exchange approval for the acquisition of CliniQuantum Ltd.
- NeuroThera will acquire approximately 54% interest in CliniQuantum.
- The acquisition involves issuing 56,600,000 common shares of NeuroThera to selling shareholders.
- The aggregate value of the consideration shares is approximately $9,459,954.20.
- CliniQuantum holds an exclusive, worldwide license for quantum simulation in clinical trial data analysis.
- The outside date for completing the transaction has been extended to June 1, 2026.
- NeuroThera shares for earn-out payments will be issued at a minimum deemed price of $0.05 per share.
Price Impact
More from SPRC